JP2006501166A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501166A5
JP2006501166A5 JP2004510825A JP2004510825A JP2006501166A5 JP 2006501166 A5 JP2006501166 A5 JP 2006501166A5 JP 2004510825 A JP2004510825 A JP 2004510825A JP 2004510825 A JP2004510825 A JP 2004510825A JP 2006501166 A5 JP2006501166 A5 JP 2006501166A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
heterologous
immunogenic
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004510825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501166A (ja
Filing date
Publication date
Priority claimed from GB0213364A external-priority patent/GB0213364D0/en
Priority claimed from GB0221689A external-priority patent/GB0221689D0/en
Application filed filed Critical
Priority claimed from PCT/EP2003/006095 external-priority patent/WO2003103706A2/en
Publication of JP2006501166A publication Critical patent/JP2006501166A/ja
Publication of JP2006501166A5 publication Critical patent/JP2006501166A5/ja
Pending legal-status Critical Current

Links

JP2004510825A 2002-06-11 2003-06-06 異種前立腺タンパク質ｐ５０１ｓを含む免疫原性組成物 Pending JP2006501166A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0213364A GB0213364D0 (en) 2002-06-11 2002-06-11 Vaccine
GB0221689A GB0221689D0 (en) 2002-09-18 2002-09-18 Vaccine
PCT/EP2003/006095 WO2003103706A2 (en) 2002-06-11 2003-06-06 Immunogenic compositions

Publications (2)

Publication Number Publication Date
JP2006501166A JP2006501166A (ja) 2006-01-12
JP2006501166A5 true JP2006501166A5 (enExample) 2006-06-22

Family

ID=29738081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510825A Pending JP2006501166A (ja) 2002-06-11 2003-06-06 異種前立腺タンパク質ｐ５０１ｓを含む免疫原性組成物

Country Status (6)

Country Link
US (1) US20060140965A1 (enExample)
EP (1) EP1511513A2 (enExample)
JP (1) JP2006501166A (enExample)
AU (1) AU2003250828A1 (enExample)
CA (1) CA2487907A1 (enExample)
WO (1) WO2003103706A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901680B2 (en) * 2005-10-19 2011-03-08 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
WO2006101503A2 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
WO2007002149A2 (en) 2005-06-21 2007-01-04 Cyto Pulse Sciences, Inc. Methods and compositions relating to a vaccine against prostate cancer
KR20250121449A (ko) 2017-03-10 2025-08-12 볼트 쓰레즈, 인크. 재조합 단백질을 고분비 수율로 생산하기 위한 조성물 및 방법
EP3592800A4 (en) * 2017-03-10 2021-01-06 Bolt Threads, Inc. COMPOSITIONS AND METHODS OF PRODUCING HIGHLY SECRETED YIELD OF RECOMBINANT PROTEIN

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046769A1 (en) * 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP1071333A4 (en) * 1998-03-20 2005-02-23 Genzyme Corp INDUCTION OF IMMUNITY AGAINST TUMOR AUTOANTIGENS
TR200100916T2 (enExample) * 1998-07-14 2002-06-21 Corixa@@Corporation
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20020009455A1 (en) * 2000-04-27 2002-01-24 Ted Lau DNA encoding a novel PROST 03 polypeptide

Similar Documents

Publication Publication Date Title
JP5479918B2 (ja) 子宮頸癌の治療のための組成物および方法
EP1053325B1 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP1108035B1 (en) Treatment of cervical cancer
WO2017191264A1 (en) Nucleic acid molecules and uses thereof
US20190343942A1 (en) Rna encoding a tumor antigen
ES2365077T3 (es) Péptido antígeno anticáncer derivado de sparc y composición farmacéutica que comprende el mismo.
RU2013152648A (ru) Аденовирус обезьян и гибридные аденовирусные векторы
JP2013537422A (ja) ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
JP2008056679A5 (enExample)
JP2020510426A5 (enExample)
JP2003530088A5 (enExample)
EP2118128B1 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
CN1921882A (zh) 同种异基因肿瘤治疗剂
RU2006132340A (ru) Слитые белки карциноэмбрионального антигена
US20230190923A1 (en) Compositions comprising ltb and pathogenic antigens, and use thereof
TWI415623B (zh) 使用小泛素相關融合蛋白表現系統製備類病毒粒子的方法
CN101096680A (zh) 一种dna疫苗真核表达载体及其在制备基因疫苗中的应用
JP2006501166A5 (enExample)
CA2532460A1 (en) Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
CN120324597A (zh) 编码肿瘤抗原表位的mRNA疫苗及其制备方法和用途
JP2007511534A5 (enExample)
CN110139875B (zh) Col14a1衍生的肿瘤抗原多肽及其应用
CN105801704B (zh) 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
TWI259206B (en) A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof
RU2005141524A (ru) Производные phl p 5а, обладающие сниженной аллергенностью и сохраненной т-клеточной реактивностью